APA (7th ed.) Citation

I, H., M, O., L, W., Z, Y., JA, N., A, B., . . . FC, G. (2022). Safety and biomarker effects of candesartan in non-hypertensive adults with prodromal Alzheimer's disease. Brain communications, 4(6), fcac270. https://doi.org/10.1093/braincomms/fcac270

Chicago Style (17th ed.) Citation

I, Hajjar, et al. "Safety and Biomarker Effects of Candesartan in Non-hypertensive Adults with Prodromal Alzheimer's Disease." Brain Communications 4, no. 6 (2022): fcac270. https://doi.org/10.1093/braincomms/fcac270.

MLA (9th ed.) Citation

I, Hajjar, et al. "Safety and Biomarker Effects of Candesartan in Non-hypertensive Adults with Prodromal Alzheimer's Disease." Brain Communications, vol. 4, no. 6, 2022, p. fcac270, https://doi.org/10.1093/braincomms/fcac270.